Response
Angiogenesis is a complex process with a relative balance between proangiogenic factors and inhibitors of angiogenesis. 1 Therapeutic angiogenesis is an attempt to enhance this natural process by the use of exogenous angiogenic growth factors or genes encoding for those growth factors. Inhibitors of angiogenesis, such as angiostatin, endostatin, thrombospondin-1, asymmetric dimethylarginine, metalloproteinase inhibitors, soluble receptors, and others, may well influence this attempt. In addition, clinical variables such as age, diabetes, or use of medications such as angiotensin-converting enzyme inhibitors, nitrates, or heparin may influence the response to exogenous angiogenesis growth factors.
The letter from Belgore et al raises the question of whether the presence of soluble Flt-1 receptors (sFlt-1) for vascular endothelial growth factor (VEGF) could account for the lack of efficacy seen at 60 days in the VEGF in Ischemia for Vascular Angiogenesis (VIVA) trial. The VIVA trial is currently the largest randomized, placebo-controlled trial in the field of therapeutic angiogenesis, with 178 patients randomized to receive placebo or 17 or 50 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 of intracoronary plus intravenous VEGF-165. At 60 days, all 3 groups had improvements in chest pain, quality of life, and exercise time compared with baseline, but no significant difference existed between groups, in large part because of a prominent placebo effect. 2 The final 120-day results demonstrated a decrease in the benefits of placebo and ongoing improvement in patients receiving high-dose VEGF, which resulted in a statistically significant improvement in angina class (Pϭ0.04) and a trend for improvement in exercise time (14 versus 47 seconds; Pϭ0.17). 3 In addition, the trial had an excellent safety profile, with all adverse events (2 deaths, 3 cancers, and 1 retinopathy) occurring in the placebo group.
The VEGF monoclonal ELISA used in the analysis of VIVA patient plasma samples demonstrated Ͼ89% recovery of VEGF-165 when exogenous VEGF-165 was spiked into human plasma. 4 The excellent recovery of VEGF immunoreactivity in our assay suggests that little or no sFlt-1 is found in human plasma, because sFlt-1 is known to inhibit the detection of VEGF-165 in this assay. We also repeated and confirmed the work of others 5 who reported the presence of sFlt-1 in gravid serum but not in nongravid serum. It is difficult to resolve the apparent discrepancies between our observations (suggesting little or no sFlt-1 in normal human plasma) and those of Belgore et al without a knowledge of their ELISA qualification data. It will also be important to rule out the possibility of a sFlt-1 cross-reactive substance being detected in their polyclonal assay format.
Further analysis of the VIVA data, including that on responders and nonresponders, is essential to provide insight into the questions raised by Belgore et al. Elevated levels of sFlt-1 or other VEGF antagonists may well influence the response to exogenously administered VEGF. Our search for the ideal therapeutic regimen will be successful only when we advance our understanding of the complex process of angiogenesis. We hope that the results gleaned from the VIVA trial will contribute to this search. 
